TC BioPharm leads the way in allogeneic gamma delta T cells
For the final post in our mini series on the potential of gamma delta (γδ) T cells for cancer immunotherapy, we’re traveling to Scotland with a visit to a company that is a poster child for Scottish enterprise.
TC (as in T cell) BioPharm are leading the way in development of allogeneic γδ T cell therapies. They’ve already completed a trial of autologous γδ T cell therapy to establish safety and now have an allogeneic phase 1 trial underway in Prague.
CEO and Founder, Dr Michael Leek, has built a company that already counts bluebird bio (NASDAQ: $BLUE) as one its partners (Link).
Co-Founder and Chief Operating Officer, Dr Angela Scott was part of the team that cloned the first mammal, “Dolly the Sheep.”
Dr Angela Scott, COO
She was recently profiled in The Herald (Link) and her cell therapy experience has been instrumental in the development of the company’s own GMP manufacturing facility in Scotland.
As the Herald article notes, the company is being positioned for a possible NASDAQ IPO in 2020, so is definitely one to watch out for.
We all remember catchy advertising slogans, and one I remember well is for the now defunct Orange mobile phone network in the UK: “The future is bright, the future is orange.”
If you’re TC BioPharm then maybe this could be construed as: “The future is bright, the future is allogeneic” (γδ T cells).
To learn more from our latest thought leader interview and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
